Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT05466396
Recruiting Observational

Lung Health of Early COPD: A Multi-center Cohort Study

NCT05466396 · tracked via the Priya Life Science Japan tracker
Sponsor
Ting YANG
Phase
Observational
Started
2022-08-01
Last updated
2025-02-17

Condition(s) studied

COPD

Investigational drug(s) / intervention(s)

smoking

smoking: Smoking history and spirometry are used to define groups

Study summary

This is a multi-center, prospective, cohort study in early COPD patients. This study aims to elucidate the lung function decline and its association with smoking and other risk factors. Other biomarkers and image markers from chest CT scan are also analyzed to investigate the lung function in early COPD patients.

Eligibility

Sex
ALL
Min age
35 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Gender: male or female 2. Age: 35-75 years old 3. post-bronchodilator spirometry: FEV1/FVC \< 0.8 and FEV1%pred ≥80% Exclusion Criteria: 1. Other diseases may affect lung function, like lung cancer, bronchiectasis, interstitial lung disease or chest surgery. 2. BMI \> 35 kg/m2 3. Dementia or other severe neurological disease 4. Pregnancy 5. Conditions that contraindicated lung function test

Primary outcome measure(s)

  • Lung function decline in Pre-COPD and Mild-COPD patients — 2 years
    FEV1 decline in Pre-COPD and Mild-COPD patients

Trial sites (2)

FacilityCityRegionStatus
China-Japan Friendship Hospital Beijing Beijing Municipality Recruiting
Affiliated Hospital of Zunyi Medical University Zunyi Guizhou Recruiting

Other trials for the same condition

Zephyr Valve Japan Post-Marketing Surveillance Recruiting
Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy Starting soon
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS Active, not recruiting
Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05466396 on ClinicalTrials.gov ↗ ← All trials in Japan